611 results on '"Bliden, Kevin P."'
Search Results
2. Development of a routine bedside CYP2C19 genotype assessment program for antiplatelet therapy guidance in a community hospital catheterization laboratory
3. Early assessment of the pharmacokinetic and pharmacodynamic effects following acetylsalicylic acid loading: toward a definition for acute therapeutic response
4. Meta-Analysis of the Performance of AI-Driven ECG Interpretation in the Diagnosis of Valvular Heart Diseases
5. Serial assessment of thrombogenicity and hemodynamics in patients with type II diabetes in a clinical research unit: Evidence for circadian variations in clot formation
6. Machine Learning - Based Bleeding Risk Predictions in Atrial Fibrillation Patients on Direct Oral Anticoagulants
7. Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes
8. Can CYP2C19 genotyping improve efficacy of antiplatelet therapy in real-life practice? Recent advances.
9. Urinary L-Type Fatty Acid-Binding Protein Predicts Oxygen Demand of COVID-19 in Initially Mild Cases
10. Clinical validation of AggreGuide A-100 ADP, a novel assay for assessing the antiplatelet effect of oral P2Y12 antagonists
11. Defining platelet response to acetylsalicylic acid: the relation between inhibition of serum thromboxane B2 and agonist-induced platelet aggregation
12. Milvexian: evaluating the factor XIa inhibitor for the treatment of acute coronary syndrome.
13. Utility of VerifyNow to assess the immediate pharmacodynamic response of chewed and swallowed aspirin: comparison with aggregometry
14. Early assessment of the pharmacokinetic and pharmacodynamic effects following acetylsalicylic acid loading: toward a definition for acute therapeutic response
15. Meta-Analysis of the Performance of AI-Driven ECG Interpretation in the Diagnosis of Valvular Heart Diseases
16. Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates
17. Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population
18. Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a case–control study
19. An overview of the utility of prasugrel hydrochloride as a treatment option for ischemic stroke.
20. D-59 | Pooled Cardiovascular Outcomes With Combined Atherectomy and Intravascular Lithotripsy in Calcified Coronary Lesions
21. C-61 | Role of Intravenous Iron for Iron Deficiency in Patients With Systolic Heart Failure
22. C-62 | Pooled Outcomes of SGLT2 Inhibitors in Acute Decompensated Heart Failure
23. C-46 | Percutaneous Coronary Intervention for Stable Coronary Artery Disease: An Updated Meta-analysis
24. Thrombogenicity and central pulse pressure to enhance prediction of ischemic event occurrence in patients with established coronary artery disease: The MAGMA-ischemia score
25. PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study
26. Gender differences in thrombogenicity among patients with angina and non-obstructive coronary artery disease
27. “Blueprinting” thrombogenicity and antithrombotic drug response at the bedside in patients presenting emergently with symptoms of acute stroke
28. An update on novel therapies for treating patients with arterial thrombosis
29. First In-Human Experience With Inhaled Acetylsalicylic Acid for Immediate Platelet Inhibition: Comparison With Chewed and Swallowed Acetylsalicylic Acid
30. Can an Old Ally Defeat a New Enemy?
31. Antiplatelet Effect Durability of a Novel, 24-Hour, Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes Mellitus
32. Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study
33. Prognostic impact of hypercoagulability and impaired fibrinolysis in acute myocardial infarction
34. Thromboxane inhibition during concurrent therapy with low-dose aspirin and over-the-counter naproxen sodium
35. Oxidized Low-Density Lipoprotein-β2-Glycoprotein I Complex But Not Free Oxidized LDL Is Associated With the Presence and Severity of Coronary Artery Disease
36. Reply to: Among patients with MINOCA women versus men have the increased risks of MACE and stroke?
37. Relation of Fish Oil Supplementation to Markers of Atherothrombotic Risk in Patients With Cardiovascular Disease Not Receiving Lipid-Lowering Therapy
38. Meta-Analysis of Direct and Indirect Comparison of Ticagrelor and Prasugrel Effects on Platelet Reactivity
39. Sex-related differences in clinical outcomes among patients with myocardial infarction with nonobstructive coronary artery disease: A systematic review and meta-analysis
40. Central aortic pulse pressure, thrombogenicity and cardiovascular risk
41. Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system
42. Association of weight gain with coronary artery disease, inflammation and thrombogenicity
43. Influence of platelet reactivity and inflammation on peri-procedural myonecrosis in East Asian patients undergoing elective percutaneous coronary intervention
44. The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel: The PARADOX Study
45. Novel Antiplatelet Agents in Cardiovascular Medicine
46. The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy
47. The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: Combined analysis of the ONSET/OFFSET and RESPOND studies
48. Urinary L-Type Fatty Acid-Binding Protein Predicts Oxygen Demand of COVID-19 in Initially Mild Cases
49. Further evidence for the use of aspirin in COVID-19
50. Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.